AUA 2018

AUA 2018: Primary Adrenal Malignancy: Insights into the Epidemiology of a Rare Histological Subset

San Francisco, CA (UroToday.com) Renal cell carcinoma (RCC) has traditionally been surgically managed. Extirpative surgery, either radical nephrectomy (RN) or partial nephrectomy (PNx), remains the standard of care for localized disease. Targeted therapies (TT), including tyrosine kinase inhibitors (TKIs) and mTOR inhibitors, have become a cornerstone of RCC therapy, specifically for metastatic RCC,  demonstrating extended progression-free survival. While the efficacy of targeted therapies is well established for metastatic RCC, its role as an adjuvant therapy is less clear.

AUA 2018: Augmenix, Inc. Announces Exciting Plans for the 2018 American Urological Association Meeting in San Francisco

Truckee, CA (UroToday.com) -- Augmenix, Inc. is pleased to announce that they will be exhibiting at this year’s American Urological Association meeting in San Francisco, California. Located at Booth 6251 Hall D, the company will be featuring their leading product, SpaceOAR® hydrogel, which is used in patients receiving radiation therapy for prostate cancer. Attendees of the AUA meeting are invited to visit the exhibit to learn about the latest developments that make SpaceOAR hydrogel the #1 rectal spacer for prostate cancer radiotherapy worldwide.

AUA 2018: Photocure to Present New Data on Cysview® at the 2018 American Urological Association Annual Meeting

Truckee, CA (UroToday.com) -- Photocure ASA announced that Photocure will be exhibiting Blue Light Cystoscopy (BLC™) with Cysview in Booth 1825, during the American Urological Association Meeting (AUA 2018) in San Francisco, CA.

New data on Cysview will be presented in at least three posters, of which two are on registry studies using real-world longitudinal data, a plenary session on Patient Reported Outcomes and during the Bladder Cancer Surgical Technique session. Dr. James McKiernan will present on "Enhanced Cystoscopy: BLC – TURBT + Surveillance Video".

AUA 2018: Results from Interim Analysis of Pivotal Phase 3 Trial of UGN-101 for Non-Surgical Treatment of Upper Tract Urothelial Cancer

Truckee, CA (UroToday.com) -- UroGen Pharma Ltd., a clinical-stage biopharmaceutical company developing treatments to address unmet needs in the field of urology, with a focus on uro-oncology,  announced a new data presentation from an interim analysis of the ongoing pivotal Phase 3 OLYMPUS clinical trial of UGN-101 (MitoGel™), an investigational mitomycin formulation for the non-surgical treatment of low-grade upper tract urothelial cancer (UTUC). The full interim analysis will be presented on Monday, May 21, 2018 in an oral presentation during the plenary session at the 113th American Urological Association's (AUA) Annual Meeting in San Francisco.

Late-Breaker Presentation for NOCTIVA™ Accepted for the 2018 American Urological Association Meeting

Truckee, CA (UroToday.com)  -- Avadel Pharmaceuticals plc announced that new data from NOCTIVA’s pivotal Phase III clinical trials will be presented at the American Urological Association (AUA) 2018 annual meeting in San Francisco as a late-breaking presentation feature in the Next Frontiers plenary session. The presentation will share new data on extending the time to first uninterrupted sleep in elderly patients with nocturia following treatment with AV002 (NOCTIVA).